Merck & Co., Inc. Cost of Goods Sold (Deprecated 2018-01-31)
Merck & Co., Inc. (MRK) reported Cost of Goods Sold (Deprecated 2018-01-31) of $3.18 billion for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-08.
Discontinued › Expense Statement
us-gaap:CostOfGoodsSold · last filed 2018-05-08
- Merck & Co., Inc. cost of goods sold (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $3.18B, a 4.43% increase year-over-year.
- Merck & Co., Inc. cost of goods sold (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $3.41B, a 2.22% increase year-over-year.
- Merck & Co., Inc. cost of goods sold (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $3.27B, a 3.96% decline year-over-year.
- Merck & Co., Inc. cost of goods sold (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $3.08B, a 13.92% decline year-over-year.
- Merck & Co., Inc. cost of goods sold (deprecated 2018-01-31) for fiscal 2017 was $12.78B, a 8.03% decline from fiscal 2016.
- Merck & Co., Inc. cost of goods sold (deprecated 2018-01-31) for fiscal 2016 was $13.89B, a 6.98% decline from fiscal 2015.
- Merck & Co., Inc. cost of goods sold (deprecated 2018-01-31) for fiscal 2015 was $14.93B, a 10.94% decline from fiscal 2014.
- Merck & Co., Inc. cost of goods sold (deprecated 2018-01-31) for fiscal 2014 was $16.77B, a 1.10% decline from fiscal 2013.
| Period end | Cost of Goods Sold (Deprecated 2018-01-31) 3 month | Cost of Goods Sold (Deprecated 2018-01-31) 3 month as first filed | Cost of Goods Sold (Deprecated 2018-01-31) 6 month | Cost of Goods Sold (Deprecated 2018-01-31) 6 month as first filed | Cost of Goods Sold (Deprecated 2018-01-31) 9 month | Cost of Goods Sold (Deprecated 2018-01-31) 9 month as first filed | Cost of Goods Sold (Deprecated 2018-01-31) 12 month | Cost of Goods Sold (Deprecated 2018-01-31) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2018-03-31 | $3.18B 10-Q · filed 2018-05-08 | $6.59B derived: sum of 2 quarters · filed 2018-05-08 | $9.86B derived: sum of 3 quarters · filed 2018-05-08 | $12.94B derived: sum of 4 quarters · filed 2018-05-08 | ||||
| 2017-12-31 | $3.41B derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $6.68B derived: sum of 2 quarters · filed 2018-02-27 | $9.76B derived: sum of 3 quarters · filed 2018-02-27 | $12.78B 10-K · filed 2018-02-27 | ||||
| 2017-09-30 | $3.27B 10-Q · filed 2017-11-07 | $6.35B derived: sum of 2 quarters · filed 2017-11-07 | $9.37B 10-Q · filed 2017-11-07 | $12.73B derived: sum of 4 quarters · filed 2018-05-08 | ||||
| 2017-06-30 | $3.08B 10-Q · filed 2017-08-08 | $6.09B 10-Q · filed 2017-08-08 | $9.46B derived: sum of 3 quarters · filed 2018-05-08 | $12.87B derived: sum of 4 quarters · filed 2018-05-08 | ||||
| 2017-03-31 | $3.05B 10-Q · filed 2018-05-08 | $3.02B 10-Q · filed 2017-05-09 | $6.38B derived: sum of 2 quarters · filed 2018-05-08 | $9.79B derived: sum of 3 quarters · filed 2018-05-08 | $13.37B derived: sum of 4 quarters · filed 2018-05-08 | |||
| 2016-12-31 | $3.33B derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $6.74B derived: sum of 2 quarters · filed 2018-02-27 | $10.32B derived: sum of 3 quarters · filed 2018-02-27 | $13.89B 10-K · filed 2018-02-27 | ||||
| 2016-09-30 | $3.41B 10-Q · filed 2017-11-07 | $6.99B derived: sum of 2 quarters · filed 2017-11-07 | $10.56B 10-Q · filed 2017-11-07 | $14.41B derived: sum of 4 quarters · filed 2018-02-27 | ||||
| 2016-06-30 | $3.58B 10-Q · filed 2017-08-08 | $7.15B 10-Q · filed 2017-08-08 | $11.00B derived: sum of 3 quarters · filed 2018-02-27 | $14.76B derived: sum of 4 quarters · filed 2018-02-27 | ||||
| 2016-03-31 | $3.57B 10-Q · filed 2017-05-09 | $7.42B derived: sum of 2 quarters · filed 2018-02-27 | $11.18B derived: sum of 3 quarters · filed 2018-02-27 | $14.94B derived: sum of 4 quarters · filed 2018-02-27 | ||||
| 2015-12-31 | $3.85B derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $7.61B derived: sum of 2 quarters · filed 2018-02-27 | $11.37B derived: sum of 3 quarters · filed 2018-02-27 | $14.93B 10-K · filed 2018-02-27 | ||||
| 2015-09-30 | $3.76B 10-Q · filed 2016-11-07 | $7.51B derived: sum of 2 quarters · filed 2016-11-07 | $11.08B 10-Q · filed 2016-11-07 | $14.83B derived: sum of 4 quarters · filed 2017-02-28 | ||||
| 2015-06-30 | $3.75B 10-Q · filed 2016-08-08 | $7.32B 10-Q · filed 2016-08-08 | $11.07B derived: sum of 3 quarters · filed 2017-02-28 | $15.29B derived: sum of 4 quarters · filed 2017-02-28 | ||||
| 2015-03-31 | $3.57B 10-Q · filed 2016-05-09 | $7.32B derived: sum of 2 quarters · filed 2017-02-28 | $11.54B derived: sum of 3 quarters · filed 2017-02-28 | $16.43B derived: sum of 4 quarters · filed 2017-02-28 | ||||
| 2014-12-31 | $3.75B derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | $7.97B derived: sum of 2 quarters · filed 2017-02-28 | $12.87B derived: sum of 3 quarters · filed 2017-02-28 | $16.77B 10-K · filed 2017-02-28 | ||||
| 2014-09-30 | $4.22B 10-Q · filed 2015-11-05 | $9.12B derived: sum of 2 quarters · filed 2015-11-05 | $13.02B 10-Q · filed 2015-11-05 | $17.63B derived: sum of 4 quarters · filed 2016-02-26 | ||||
| 2014-06-30 | $4.89B 10-Q · filed 2015-08-06 | $8.80B 10-Q · filed 2015-08-06 | $13.40B derived: sum of 3 quarters · filed 2016-02-26 | $17.51B derived: sum of 4 quarters · filed 2016-02-26 | ||||
| 2014-03-31 | $3.90B 10-Q · filed 2015-05-07 | $8.51B derived: sum of 2 quarters · filed 2016-02-26 | $12.61B derived: sum of 3 quarters · filed 2016-02-26 | $16.90B derived: sum of 4 quarters · filed 2016-02-26 | ||||
| 2013-12-31 | $4.61B derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-26 | $8.71B derived: sum of 2 quarters · filed 2016-02-26 | $12.99B derived: sum of 3 quarters · filed 2016-02-26 | $16.95B 10-K · filed 2016-02-26 | ||||
| 2013-09-30 | $4.10B 10-Q · filed 2014-11-10 | $8.39B derived: sum of 2 quarters · filed 2014-11-10 | $12.35B 10-Q · filed 2014-11-10 | $16.51B derived: sum of 4 quarters · filed 2015-02-27 | ||||
| 2013-06-30 | $4.28B 10-Q · filed 2014-08-07 | $8.24B 10-Q · filed 2014-08-07 | $12.40B derived: sum of 3 quarters · filed 2015-02-27 | $16.54B derived: sum of 4 quarters · filed 2015-02-27 | ||||
| 2013-03-31 | $3.96B 10-Q · filed 2014-05-08 | $8.12B derived: sum of 2 quarters · filed 2015-02-27 | $12.26B derived: sum of 3 quarters · filed 2015-02-27 | $16.37B derived: sum of 4 quarters · filed 2015-02-27 | ||||
| 2012-12-31 | $4.16B derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-27 | $8.30B derived: sum of 2 quarters · filed 2015-02-27 | $12.41B derived: sum of 3 quarters · filed 2015-02-27 | $16.45B 10-K · filed 2015-02-27 | ||||
| 2012-09-30 | $4.14B 10-Q · filed 2013-11-07 | $8.25B derived: sum of 2 quarters · filed 2013-11-07 | $12.29B 10-Q · filed 2013-11-07 | $16.46B derived: sum of 4 quarters · filed 2014-02-27 | ||||
| 2012-06-30 | $4.11B 10-Q · filed 2013-08-07 | $8.15B 10-Q · filed 2013-08-07 | $12.32B derived: sum of 3 quarters · filed 2014-02-27 | $16.68B derived: sum of 4 quarters · filed 2014-02-27 | ||||
| 2012-03-31 | $4.04B 10-Q · filed 2013-05-09 | $8.21B derived: sum of 2 quarters · filed 2014-02-27 | $12.56B derived: sum of 3 quarters · filed 2014-02-27 | $16.85B derived: sum of 4 quarters · filed 2014-02-27 | ||||
| 2011-12-31 | $4.18B derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-27 | $8.53B derived: sum of 2 quarters · filed 2014-02-27 | $12.81B derived: sum of 3 quarters · filed 2014-02-27 | $16.87B 10-K · filed 2014-02-27 | ||||
| 2011-09-30 | $4.35B 10-Q · filed 2012-11-09 | $8.64B derived: sum of 2 quarters · filed 2012-11-09 | $12.70B 10-Q · filed 2012-11-09 | $17.14B derived: sum of 4 quarters · filed 2013-02-28 | ||||
| 2011-06-30 | $4.28B 10-Q · filed 2012-08-07 | $8.34B 10-Q · filed 2012-08-07 | $12.78B derived: sum of 3 quarters · filed 2013-02-28 | $16.97B derived: sum of 4 quarters · filed 2013-02-28 | ||||
| 2011-03-31 | $4.06B 10-Q · filed 2012-05-08 | $8.50B derived: sum of 2 quarters · filed 2013-02-28 | $12.69B derived: sum of 3 quarters · filed 2013-02-28 | $17.24B derived: sum of 4 quarters · filed 2013-02-28 | ||||
| 2010-12-31 | $4.44B derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-28 | $8.63B derived: sum of 2 quarters · filed 2013-02-28 | $13.18B derived: sum of 3 quarters · filed 2013-02-28 | $18.40B 10-K · filed 2013-02-28 | ||||
| 2010-09-30 | $4.19B 10-Q · filed 2011-11-08 | $4.19B 10-Q · filed 2010-11-08 | $8.74B derived: sum of 2 quarters · filed 2011-11-08 | $13.96B 10-Q · filed 2011-11-08 | $13.96B 10-Q · filed 2010-11-08 | $18.86B derived: sum of 4 quarters · filed 2012-02-28 | ||
| 2010-06-30 | $4.55B 10-Q · filed 2011-08-08 | $4.55B 10-Q · filed 2010-08-06 | $9.76B 10-Q · filed 2011-08-08 | $9.76B 10-Q · filed 2010-08-06 | $14.67B derived: sum of 3 quarters · filed 2012-02-28 | $16.10B derived: sum of 4 quarters · filed 2012-02-28 | ||
| 2010-03-31 | $5.22B 10-Q · filed 2011-05-09 | $5.22B 10-Q · filed 2010-05-07 | $10.12B derived: sum of 2 quarters · filed 2012-02-28 | $11.55B derived: sum of 3 quarters · filed 2012-02-28 | $12.90B derived: sum of 4 quarters · filed 2012-02-28 | |||
| 2009-12-31 | $4.90B derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-28 | $6.33B derived: sum of 2 quarters · filed 2012-02-28 | $7.69B derived: sum of 3 quarters · filed 2012-02-28 | $9.02B 10-K · filed 2012-02-28 | $9.02B 10-K · filed 2010-03-01 | |||
| 2009-09-30 | $1.43B 10-Q · filed 2010-11-08 | $2.78B derived: sum of 2 quarters · filed 2010-11-08 | $4.12B 10-Q · filed 2010-11-08 | |||||
| 2009-06-30 | $1.35B 10-Q · filed 2010-08-06 | $2.69B 10-Q · filed 2010-08-06 | ||||||
| 2009-03-31 | $1.33B 10-Q · filed 2010-05-07 | |||||||
| 2008-12-31 | $5.58B 10-K · filed 2011-02-28 | $5.58B 10-K · filed 2010-03-01 | ||||||
| 2007-12-31 | $6.14B 10-K · filed 2010-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |